Our top pick for
iCAD, Inc is a health information services business based in the US. iCAD shares (ICAD) are listed on the NASDAQ and all prices are listed in US Dollars. iCAD employs 135 staff and has a trailing 12-month revenue of around USD$29.4 million.
Since the stock market crash in March caused by coronavirus, iCAD's share price has had significant negative movement.
Its last market close was USD$9.03, which is 22.42% down on its pre-crash value of USD$11.64 and 52.79% up on the lowest point reached during the March crash when the shares fell as low as USD$5.91.
If you had bought USD$1,000 worth of iCAD shares at the start of February 2020, those shares would have been worth USD$833.89 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,048.74.
|Latest market close||USD$9.03|
|52-week range||USD$5.91 - USD$15.31|
|50-day moving average||USD$9.6065|
|200-day moving average||USD$10.2899|
|Wall St. target price||USD$14.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.703|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-6.04%|
|1 month (2020-10-30)||-7.48%|
|3 months (2020-08-28)||-10.68%|
|6 months (2020-05-29)||-23.08%|
|1 year (2019-11-29)||20.24%|
|2 years (2018-11-30)||108.06%|
|3 years (2017-11-30)||151.53%|
|5 years (2015-11-30)||121.32%|
|Revenue TTM||USD$29.4 million|
|Gross profit TTM||USD$24.6 million|
|Return on assets TTM||-14.27%|
|Return on equity TTM||-109.73%|
|Market capitalisation||USD$223.3 million|
TTM: trailing 12 months
There are currently 1.1 million iCAD shares held short by investors – that's known as iCAD's "short interest". This figure is 2.7% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting iCAD shares can be evaluated.
iCAD's "short interest ratio" (SIR) is the quantity of iCAD shares currently shorted divided by the average quantity of iCAD shares traded daily (recently around 244187.75055679). iCAD's SIR currently stands at 4.49. In other words for every 100,000 iCAD shares traded daily on the market, roughly 4490 shares are currently held short.
However iCAD's short interest can also be evaluated against the total number of iCAD shares, or, against the total number of tradable iCAD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iCAD's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 iCAD shares in existence, roughly 50 shares are currently held short) or 0.0526% of the tradable shares (for every 100,000 tradable iCAD shares, roughly 53 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iCAD.
Find out more about how you can short iCAD stock.
We're not expecting iCAD to pay a dividend over the next 12 months.
iCAD's shares were split on a 1:5 basis on 16 August 2012. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iCAD shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for iCAD shares which in turn could have impacted iCAD's share price.
Over the last 12 months, iCAD's shares have ranged in value from as little as $5.91 up to $15.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while iCAD's is 1.3491. This would suggest that iCAD's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer's network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.